July 18-20 2017 | Boston

Register by Friday, June 23 to save up to $500

 

Day One
Wednesday July 19, 2017

Day Two
Thursday July 20, 2017

08.00
Registration & Coffee

09.00
Chair’s Opening Remarks

Taking Learnings from the Clinic to Advance Preclinical Models & Translational Decision Making

09.10
Developing Checkpoint Target Humanized Models For Preclinical Efficacy Assessment

Synopsis

  • Lack of animal models for efficacy evaluation of human therapeutic antibodies for cancer immunotherapies
  • HuGEMM models, expressing chimeric checkpoint targets with human extracellular domains, allow the evaluation of specific human biological therapies in vivo

09.40
Improving Translational Decision Making to Influence Clinical Trial Design & Determine Endpoints

  • Jason Fleming Chairman of Gastrointestinal Oncology, Moffitt Cancer Center

Synopsis

  • Bridging the model to human gap through effective and predictive biomarker strategy
  • Improving characterization of preclinical models
  • Ensuring more robust and rigorous translational research that ultimately help shorten development timelines

10.10
Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

  • Rick Huntress Director of Business Development, Clinical & In Vivo Services, The Jackson Laboratory

Synopsis

  • The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provide for a more robust myeloid compartment after humanization
  • Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX tumors

10.40
Morning Refreshments & Speed Networking


In Vivo Model Advancements: Syngeneic Models

11.40 Development and Application of GEMM and GEMMderived Syngeneic Models in Immuno-Oncology Drug Discovery

  • Addressing the preclinical needs of GEMM and GEMM-derived syngeneic models for IO drug discovery
  • How to improve characterization of above models to help model selection
  • Providing examples of utilization of GEMM and GEMM-derived syngeneic models in IO drug discovery

Hui Wang, Principal Scientist, In Vivo Pharmacology, Oncology Research & Development, Pfizer

12.10 Identification of Novel Immune Regulators of Tumor Growth Using High-Throughput Screening In Vivo

  • We have generated a comprehensive library of substantially all human extracellular proteins including secreted proteins and the extracellular domains of membrane-bound proteins in soluble form
  • A portion of this library called the immunome contains >700 proteins with structural features characteristic of immuneactivators and checkpoints
  • The immunome library was screened in four syngeneic mouse tumor models in vivo using RIPPSSM (Rapid In vivo Protein Production System)
  • Several hits were identified and CD80-Fc was prioritized for therapeutic development based on relative efficacy and tumor immune cell profiles

Tom Brennan, Vice President, Pharmacology & Bioanalytics, FivePrime Therapeutics

12.40 Preclinical Mouse Models of Cancer Via Transposon- Mediated Mutagenesis or Gene Transfer

  • The development of the Sleeping Beauty (SB) transposon for forward genetic screens in mice: Immunoproficient, autochthonous models of cancer with clinically relevant genetic and biologic features
  • SB screens for sarcoma and mammary cancer: Identification of drivers of specific tumor biology
  • Using transposon-mediated gene delivery and CRISPR/Cas9 to model cancer in living mice
  • Porcine models of cancer

David Largaespada, American Cancer Society Research Professor, Department of Pediatrics, Masonic Cancer Center, University of Minnesota

13.10 Networking Lunch


In Vivo Model Advancements: PDX Models

14.10 The Use of PDX Models to Support Oncology Drug Development

  • Standard-of-care treatment from the perspective of response rates in the clinic and response rates in PDX
  • Evaluating response of PDX to standard-of-care treatment to validate this hypothesis and to identify dosages and schedules that can be used to identify sensitive and resistant PDX models

Edward Rosfjord, Senior Principal Scientist, Pfizer

14.40 Highly Characterized Patient-derived Xenograft Collections for Preclinical Studies

  • Use of highly characterized PDX models allow efficient preclinical drug screening
  • Ex vivo proliferation studies using PDX models mirrors in vivo studies

Mohit Sachdeva, Senior Scientist, Horizon Discovery

15.10 Vascular Phenotyping in PDX models using Multimodal Imaging

  • Multimodal imaging of PDX models
  • Translational relevance of PDX models of head and neck cancer
  • Imaging-guided preclinical trials of vascular targeted therapies

Mukund Seshadri, Professor of Oncology, Departments of Pharmacology & Therapeutics, Oral Medicine/Head & Neck Surgery, Roswell Park Cancer Institute

This session will finish at 15.25


Enhancing the Use of Humanized Mice Models in Preclinical Studies

11.40 Addressing the Latest Advancements in the Development of Routine Humanized Mice for Immunotherapies

  • Discussing the latest developments in humanized mice modeling
  • Presenting data from studies utilizing humanized mice for IO therapeutic development

Michael Brehm, Associate Professor, The Robert and Sandra Glass Term Chair in Diabetes, University of Massachusetts Medical School

12.10 Humanized Mouse Models for Drug Discovery Research

  • Utilization of human cancer cell lines to model different aspects of human cancers
  • Discussing the relevance of humanized mouse cell subset profiles and how they compared to ex vivo human tumors and syngeneic models
  • Leveraging humanized systems for clinical translation, combination therapies, and biomarker development

Barbara Joyce-Shaikh, Associate Principal Scientist, Merck

12.40 Focal Radiation in Combination with Chemotherapy & Immunotherapy

  • Uses of focal radiation in preclinical oncology models
  • Combining focal radiation with chemotherapy in a human triple negative breast cancer model
  • Focal radiation in combination with immuno-therapy in a syngeneic murine glioblastoma model

Maryland Franklin, Vice President, Scientific Development, MI Bioresearch

This session will finish at 12.55

13.10 Networking Lunch


Harnessing Ex Vivo Assays for the Development of Cell Therapies

14.10 Developing Ex Vivo Preclinical Models to Enhance Translation from In Vitro to In Vivo for Cell Therapies

  • What models are being utilized to predict efficacy of engineered T-cell therapies?
  • Addressing the limitations in current models and how the industry are optimizing preclinical strategies for CAR-T cell therapies

Gregor Adams, Principal Scientist, Kite Pharma Inc

14.40 Preclinical Modeling of Chimeric Antigen Receptor T Cell Therapy and Combination Immunotherapy

  • Discussing preclinical modeling in CAR-T cell therapy
  • Addressing how preclinical modeling can be used for the evaluation of CAR-T cell toxicities
  • Presenting strategies for the development of combination immunotherapy

Saad Kenderian, Assistant Professor of Medicine & Oncology, Mayo Clinic

15.10 Exploring Tumor Microenvironment Using Immuno-PET as a Predictive Tool

  • The effectiveness of immunotherapies is a direct result of changes they evoke in the tumor microenvironment
  • Identifying reproducible patterns in responders and nonresponders is key to explaining the failure or success of a therapy
  • Using immunoPET to explore dynamics of immune infiltrates in response to therapy

Mohammad Rashidian, Research Fellow, Boston Children Hospital, Harvard Medical School

15.40
Afternoon Refreshments & Poster Session

16.10
Tumor Models Interactive Round-Table Session

Synopsis

In this 1 hour session, you will have the opportunity to catch up on the latest advancements within the field and learn from your fellow colleagues in this interactive format. The topics that will be discussed are the following: 

  1. Developing predictive humanized mice- What are the current limitations?
  2. What added benefits can organoid cultures bring to preclinical studies?
  3. Fundamental preclinical experimental design: Setting up for clinical success
  4. How can we use preclinical models optimize the predictability of novel combination therapies?

17.10
Chair’s Closing Remarks

17.15
Drinks Reception Hosted By Crown Bioscience